SCHEMBL30316033

SCHEMBL30316033

Cn1ncc2ccc(-c3csc(NC(=O)CNC(=O)OC(C)(C)C)n3)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 4/20 0.48
▸ HDAC1 Q13547 3/20 0.48
▸ HDAC2 Q92769 3/20 0.48
▸ HDAC10 Q969S8 3/20 0.48
▸ HDAC8 Q9BY41 2/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.44
▸ NCOR2 Q9Y618 1/20 0.44
▸ MEN1 O00255 6/20 0.43
▸ KMT2A Q03164 6/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ RAB9A P51151 5/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ CASP3 P42574 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22290770 0.86 MEN1 (0.47) HDAC1HDAC6MEN1KMT2ASMN1; SMN2
SCHEMBL22306416 0.86 HDAC3 (0.47) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL30315944 0.86 HDAC3 (0.47) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL21225187 0.81 HDAC1 (0.55) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL31173493 0.81 RAB9A (0.47) MEN1KMT2ASMN1; SMN2L3MBTL1POLB
SCHEMBL22290415 0.81 RAB9A (0.47) MEN1KMT2ASMN1; SMN2L3MBTL1POLB
SCHEMBL30058894 0.81 HDAC3 (0.46) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL25511379 0.81 HDAC3 (0.46) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL23714940 0.81 HDAC3 (0.52) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL22306734 0.81 HDAC3 (0.53) HDAC3HDAC1HDAC2HDAC10HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HDAC3 231/4885HDAC1 242/4885HDAC2 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback